Aetna (NYSE:AET)‘s stock had its “outperform” rating restated by research analysts at Wells Fargo & Company in a note issued to investors on Monday. They presently have a $208.00 price target on the stock, up from their previous price target of $200.00. Wells Fargo & Company’s target price would indicate a potential upside of 16.40% from the company’s current price.
AET has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Aetna from a “hold” rating to a “buy” rating and set a $174.00 price objective for the company in a research report on Thursday, October 12th. Deutsche Bank raised their price objective on shares of Aetna from $157.00 to $163.00 and gave the company a “hold” rating in a research report on Monday, August 7th. Jefferies Group raised their price objective on shares of Aetna from $165.00 to $185.00 and gave the company a “hold” rating in a research report on Wednesday, November 1st. BMO Capital Markets started coverage on shares of Aetna in a research report on Monday, October 16th. They issued a “market perform” rating and a $175.00 price objective for the company. Finally, Raymond James Financial upgraded shares of Aetna from a “market perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a research report on Friday, November 3rd. Eleven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $174.14.
Aetna (NYSE AET) opened at $178.69 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.53 and a quick ratio of 0.53. Aetna has a 1 year low of $116.04 and a 1 year high of $192.37. The company has a market cap of $58,274.07, a P/E ratio of 17.50, a PEG ratio of 1.63 and a beta of 0.61.
In other Aetna news, President Karen S. Lynch sold 15,271 shares of Aetna stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $161.91, for a total transaction of $2,472,527.61. Following the transaction, the president now directly owns 64,261 shares of the company’s stock, valued at $10,404,498.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Margaret M. Mccarthy sold 10,288 shares of Aetna stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $162.85, for a total transaction of $1,675,400.80. Following the transaction, the executive vice president now directly owns 33,563 shares in the company, valued at $5,465,734.55. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.
Several hedge funds have recently bought and sold shares of AET. FMR LLC raised its stake in shares of Aetna by 73.8% during the second quarter. FMR LLC now owns 13,736,800 shares of the company’s stock worth $2,085,659,000 after acquiring an additional 5,833,567 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Aetna by 9,446.2% during the second quarter. Janus Henderson Group PLC now owns 4,328,900 shares of the company’s stock worth $657,255,000 after acquiring an additional 4,283,553 shares in the last quarter. Capital World Investors raised its stake in shares of Aetna by 8.9% during the second quarter. Capital World Investors now owns 20,769,004 shares of the company’s stock worth $3,153,358,000 after acquiring an additional 1,688,767 shares in the last quarter. Orbimed Advisors LLC raised its stake in shares of Aetna by 57.3% during the third quarter. Orbimed Advisors LLC now owns 1,396,500 shares of the company’s stock worth $222,057,000 after acquiring an additional 508,600 shares in the last quarter. Finally, Samlyn Capital LLC bought a new position in shares of Aetna in the second quarter worth approximately $77,170,000. 88.03% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Aetna (AET) Stock Rating Reaffirmed by Wells Fargo & Company” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://stocknewstimes.com/2017/12/06/aetna-aet-stock-rating-reaffirmed-by-wells-fargo-company.html.
Aetna Company Profile
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.